Lu et al. (121) tested combination anti-CTLA4 and anti-PD1 (ICI) with either dasatinib (tyrosine kinase inhibitor), cabozantinib (tyrosine kinase inhibitor), or BEZ235 (phosphoinositide 3-kinase/mTOR dual inhibitor) to target tumor MDSCs in a mouse mCRPC model. Here, CTLA4 is linked to neoplasm.